{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:37:34Z","timestamp":1779115054819,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,3,31]],"date-time":"2008-03-31T00:00:00Z","timestamp":1206921600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>At present pathogenic mechanisms of cancer cachexia are poorly understood. Previous evidence in animal models implicates the melanocortin-4 receptor gene (<jats:italic>MC4R<\/jats:italic>) in the development of cancer cachexia. In humans, <jats:italic>MC4R<\/jats:italic> mutations that lead to an impaired receptor function are associated with obesity; in contrast, the most frequent polymorphism (Val103Ile, rs2229616; heterozygote frequency approximately 2%) was shown to be negatively associated with obesity. We tested if cancer patients that are homo-\/heterozygous for the Val103Ile polymorphism are more likely to develop cachexia and\/or a loss of appetite than non-carriers of the 103Ile-allele.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>BMI (body mass index in kg\/m<jats:sup>2<\/jats:sup>) of 509 patients (295 males) with malignant neoplasms was determined; additionally patients were asked about premorbid\/pretherapeutical changes of appetite and weight loss. Cachexia was defined as a weight loss of at least 5% prior to initiation of therapy; to fulfil this criterion this weight loss had to occur independently of other plausible reasons; in single cases weight loss was the initial reason for seeing a physician. The average age in years (\u00b1 SD) was 59.0 \u00b1 14.5 (males: 58.8 \u00b1 14.0, females 59.2 \u00b1 14.0). Blood samples were taken for genotyping of the Val103Ile by PCR- RFLP.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Most of the patients suffered from lymphoma, leukaemia and gastrointestinal tumours. 107 of the patients (21%) fulfilled our criteria for cancer cachexia. We did not detect association between the Val103Ile polymorphism and cancer cachexia. However, if we exploratively excluded the patients with early leucaemic stages, we detected a trend towards the opposite effect (p &lt; 0.05); heterozygotes for the 103Ile-allele developed cancer cachexia less frequently in comparison to the rest of the study group. Changes of appetite were not associated with the 103Ile-allele carrier status (p &gt; 0.39).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Heterozygotes for the 103Ile-allele are not more prone to develop cancer cachexia than patients without this allele; possibly, Ile103 carriers might be more resistant to cancer cachexia in patients with solid tumors. Further studies of the melanocortinergic system in cachexia of patients with solid tumors are warranted.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-8-85","type":"journal-article","created":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T06:14:00Z","timestamp":1207030440000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Val103Ile polymorphism of the melanocortin-4 receptor gene (MC4R) in cancer cachexia"],"prefix":"10.1186","volume":"8","author":[{"given":"Susanne","family":"Knoll","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabiene","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anke","family":"Hinney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Scherag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Neubauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Hebebrand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,3,31]]},"reference":[{"key":"1023_CR1","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1476-4598-2-36","volume":"2","author":"ME Martignoni","year":"2003","unstructured":"Martignoni ME, Kunze P, Friess H: Cancer cachexia. Mol Cancer. 2003, 2: 36-10.1186\/1476-4598-2-36.","journal-title":"Mol Cancer"},{"issue":"Suppl 3","key":"1023_CR2","first-page":"4","volume":"21","author":"JM Argiles","year":"2006","unstructured":"Argiles JM, Busquets S, Lopez-Soriano FJ, Figueras M: Pathophysiology of neoplasic cachexia. Nutr Hosp. 2006, 21 (Suppl 3): 4-9.","journal-title":"Nutr Hosp"},{"key":"1023_CR3","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/nrc927","volume":"2","author":"MJ Tisdale","year":"2002","unstructured":"Tisdale MJ: Cachexia in cancer patients. Nat Rev Cancer. 2002, 2: 862-71. 10.1038\/nrc927.","journal-title":"Nat Rev Cancer"},{"key":"1023_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0167-5273(02)00235-8","volume":"85","author":"KC Fearon","year":"2002","unstructured":"Fearon KC, Moses AG: Cancer cachexia. Int J Cardiol. 2002, 85: 73-81. 10.1016\/S0167-5273(02)00235-8.","journal-title":"Int J Cardiol"},{"key":"1023_CR5","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S1072-7515(03)00382-X","volume":"197","author":"N MacDonald","year":"2003","unstructured":"MacDonald N, Easson AM, Mazurak VC, Dunn GP, Baracos VE: Understanding and managing cancer cachexia. J Am Coll Surg. 2003, 197: 143-61. 10.1016\/S1072-7515(03)00382-X.","journal-title":"J Am Coll Surg"},{"key":"1023_CR6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3322\/canjclin.52.2.72","volume":"52","author":"A Inui","year":"2002","unstructured":"Inui A: Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin. 2002, 52: 72-91.","journal-title":"CA Cancer J Clin"},{"key":"1023_CR7","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1097\/01.ju.0000121440.82581.d3","volume":"171","author":"HL Kim","year":"2004","unstructured":"Kim HL, Han KR, Zisman A, Figlin RA, Belldegrun AS: Cachexia-like symptoms predict a worse prognosis in localized t1 renal cell carcinoma. J Urol. 2004, 171: 1810-3. 10.1097\/01.ju.0000121440.82581.d3.","journal-title":"J Urol"},{"issue":"2","key":"1023_CR8","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/1097-0142(19890115)63:2<330::AID-CNCR2820630221>3.0.CO;2-U","volume":"63","author":"M Grosvenor","year":"1989","unstructured":"Grosvenor M, Bulcavage L, Chlebowski RT: Symptoms potentially influencing weight loss in a cancer population. Correlations with primary site, nutritional status, and chemotherapy administration. Cancer. 1989, 63 (2): 330-4. 10.1002\/1097-0142(19890115)63:2<330::AID-CNCR2820630221>3.0.CO;2-U.","journal-title":"Cancer"},{"key":"1023_CR9","first-page":"1432","volume":"61","author":"DL Marks","year":"2001","unstructured":"Marks DL, Ling N, Cone RD: Role of the central melanocortin system in cachexia. Cancer Res. 2001, 61: 1432-8.","journal-title":"Cancer Res"},{"key":"1023_CR10","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0092-8674(00)81865-6","volume":"88","author":"D Huszar","year":"1997","unstructured":"Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, Gu W, Kesterson RA, Boston BA, Cone RD, Smith FJ, Campfield LA, Burn P, Lee F: Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell. 1997, 88: 131-41. 10.1016\/S0092-8674(00)81865-6.","journal-title":"Cell"},{"key":"1023_CR11","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1210\/endo.142.8.8324","volume":"142","author":"BE Wisse","year":"2001","unstructured":"Wisse BE, Frayo RS, Schwartz MW, Cummings DE: Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. Endocrinology. 2001, 142: 3292-301. 10.1210\/en.142.8.3292.","journal-title":"Endocrinology"},{"key":"1023_CR12","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1210\/en.2005-0142","volume":"146","author":"S Markison","year":"2005","unstructured":"Markison S, Foster AC, Chen C, Brookhart GB, Hesse A, Hoare SR, Fleck BA, Brown BT, Marks DL: The regulation of feeding and metabolic rate and the prevention of murine cancer cachexia with a small-molecule melanocortin-4 receptor antagonist. Endocrinology. 2005, 146: 2766-73. 10.1210\/en.2005-0142.","journal-title":"Endocrinology"},{"key":"1023_CR13","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.domaniend.2005.02.027","volume":"29","author":"JL Sartin","year":"2005","unstructured":"Sartin JL, Wagner CG, Marks DL, Daniel JA, McMahon CD, Obese FY, Partridge C: Melanocortin-4 receptor in sheep: a potential site for therapeutic intervention in disease models. Domest Anim Endocrinol. 2005, 29: 446-55. 10.1016\/j.domaniend.2005.02.027.","journal-title":"Domest Anim Endocrinol"},{"key":"1023_CR14","doi-asserted-by":"publisher","first-page":"5166","DOI":"10.1016\/j.bmc.2007.05.026","volume":"15","author":"JA Tran","year":"2007","unstructured":"Tran JA, Tucci FC, Jiang W, Marinkovic D, Chen CW, Arellano M, Markison S, Fleck BA, Wen J, White NS, Pontillo J, Saunders J, Marks D, Hoare SR, Madan A, Foster AC, Chen C: Pyrrolidininones as orally bioavailable antagonists of the human melanocortin-4 receptor with anti-cachectic activity. Bioorg Med Chem. 2007, 15: 5166-76. 10.1016\/j.bmc.2007.05.026.","journal-title":"Bioorg Med Chem"},{"issue":"12","key":"1023_CR15","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.2174\/156802607780906663","volume":"7","author":"AC Foster","year":"2007","unstructured":"Foster AC, Chen C: Melanocortin-4 receptor antagonists as potential therapeutics in the treatment of cachexia. Curr Top Med Chem. 2007, 7 (12): 1131-6. 10.2174\/156802607780906663.","journal-title":"Curr Top Med Chem"},{"key":"1023_CR16","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1172\/JCI9238","volume":"106","author":"C Vaisse","year":"2000","unstructured":"Vaisse C, Clement K, Durand E, Hercberg S, Guy-Grand B, Froguel P: Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J Clin Invest. 2000, 106: 253-62. 10.1172\/JCI9238.","journal-title":"J Clin Invest"},{"key":"1023_CR17","doi-asserted-by":"publisher","first-page":"4258","DOI":"10.1210\/jc.2003-030233","volume":"88","author":"A Hinney","year":"2003","unstructured":"Hinney A, Hohmann S, Geller F, Vogel C, Hess C, Wermter AK, Brokamp B, Goldschmidt H, Siegfried W, Remschmidt H, Sch\u00e4fer H, Gudermann T, Hebebrand J: Melanocortin-4 receptor gene: case-control study and transmission disequilibrium test confirm that functionally relevant mutations are compatible with a major gene effect for extreme obesity. J Clin Endocrinol Metab. 2003, 88: 4258-67. 10.1210\/jc.2003-030233.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"1023_CR18","doi-asserted-by":"publisher","first-page":"5632","DOI":"10.1210\/jc.2005-0519","volume":"90","author":"YX Tao","year":"2005","unstructured":"Tao YX, Segaloff DL: Functional Analyses of Melanocortin-4 Receptor Mutations Identified from Patients with Binge Eating Disorder and Non-obese or Obese Subjects. J Clin Endocrinol Metab. 2005, 90 (10): 5632-8. 10.1210\/jc.2005-0519.","journal-title":"J Clin Endocrinol Metab"},{"key":"1023_CR19","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1210\/jcem.84.4.5728","volume":"84","author":"A Hinney","year":"1999","unstructured":"Hinney A, Schmidt A, Nottebom K, Heib\u00fclt O, Becker I, Ziegler A, Gerber G, Sina M, G\u00f6rg T, Mayer H, Siegfried W, Fichter M, Remschmidt H, Hebebrand J: Several mutations in the melanocortin-4 receptor gene including a nonsense and a frameshift mutation associated with dominantly inherited obesity in humans. J Clin Endocrinol Metab. 1999, 84: 1483-6. 10.1210\/jc.84.4.1483.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1023_CR20","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1210\/jc.2005-2056","volume":"91","author":"A Hinney","year":"2006","unstructured":"Hinney A, Bettecken T, Tarnow P, Brumm H, Reichwald K, Lichtner P, Scherag A, Nguyen TT, Schlumberger P, Rief W, Vollmert C, Illig T, Wichmann HE, Sch\u00e4fer H, Platzer M, Biebermann H, Meitinger T, Hebebrand J: Prevalence, Spectrum and Functional Characterization of Melanocortin-4 Receptor Gene Mutations in a Representative Population-based Sample and Obese Adults from Germany. J Clin Endocrinol Metab. 2006, 91 (5): 1761-9. 10.1210\/jc.2005-2056.","journal-title":"J Clin Endocrinol Metab"},{"key":"1023_CR21","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1086\/382490","volume":"74","author":"F Geller","year":"2004","unstructured":"Geller F, Reichwald K, Dempfle A, Illig T, Vollmert C, Herpertz S, Siffert W, Platzer M, Hess C, Gudermann T, Biebermann H, Wichmann HE, Sch\u00e4fer H, Hinney A, Hebebrand J: Melanocortin-4 receptor gene variant I103 is negatively associated with obesity. Am J Hum Genet. 2004, 74: 572-81. 10.1086\/382490.","journal-title":"Am J Hum Genet"},{"key":"1023_CR22","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1136\/jmg.2004.027011","volume":"42","author":"IM Heid","year":"2005","unstructured":"Heid IM, Vollmert C, Hinney A, D\u00f6ring A, Geller F, L\u00f6wel H, Wichmann HE, Illig T, Hebebrand J, Kronenberg F, KORA Group: Association of the 103I MC4R allele with decreased body mass in 7937 participants of two population based surveys. J Med Genet. 2005, 42: e21-10.1136\/jmg.2004.027011.","journal-title":"J Med Genet"},{"issue":"9","key":"1023_CR23","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/sj.ijo.0803609","volume":"31","author":"EH Young","year":"2007","unstructured":"Young EH, Wareham NJ, Farooqi S, Hinney A, Hebebrand J, Scherag A, O'rahilly S, Barroso I, Sandhu MS: The V103I polymorphism of the MC4R gene and obesity: population based studies and meta-analysis of 29563 individuals. Int J Obes (Lond). 2007, 31 (9): 1437-41. 10.1038\/sj.ijo.0803609.","journal-title":"Int J Obes (Lond)"},{"issue":"23","key":"1023_CR24","doi-asserted-by":"publisher","first-page":"7277","DOI":"10.1021\/bi0600300","volume":"45","author":"Z Xiang","year":"2006","unstructured":"Xiang Z, Litherland SA, Sorensen NB, Proneth B, Wood MS, Shaw AM, Millard WJ, Haskell-Luevano C: Pharmacological Characterization of 40 Human Melanocortin-4 Receptor Polymorphisms with the Endogenous Proopiomelanocortin-Derived Agonists and the Agouti-Related Protein (AGRP) Antagonist. Biochemistry. 2006, 45 (23): 7277-88. 10.1021\/bi0600300.","journal-title":"Biochemistry"},{"issue":"2","key":"1023_CR25","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.cmet.2006.01.007","volume":"3","author":"H Biebermann","year":"2006","unstructured":"Biebermann H, Castaneda TR, van Landeghem F, von Deimling A, Escher F, Brabant G, Hebebrand J, Hinney A, Tsch\u00f6p MH, Gr\u00fcters A, Krude H: A role for beta-melanocyte-stimulating hormone in human body-weight regulation. Cell Metab. 2006, 3 (2): 141-6. 10.1016\/j.cmet.2006.01.007.","journal-title":"Cell Metab"},{"key":"1023_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/00001648-199501000-00012","volume":"6","author":"GS Perry","year":"1995","unstructured":"Perry GS, Byers TE, Mokdad AH, Serdula MK, Williamson DF: The validity of self-reports of past body weights by U.S. adults. Epidemiology. 1995, 6: 61-6. 10.1097\/00001648-199501000-00012.","journal-title":"Epidemiology"},{"key":"1023_CR27","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/sj.ejcn.1600601","volume":"52","author":"K Klipstein-Grobusch","year":"1998","unstructured":"Klipstein-Grobusch K, Kroke A, Boeing H: Reproducibility of self-reported past body weight. Eur J Clin Nutr. 1998, 52: 525-8. 10.1038\/sj.ejcn.1600601.","journal-title":"Eur J Clin Nutr"},{"key":"1023_CR28","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/sj.ijo.802195","volume":"27","author":"K Tamakoshi","year":"2003","unstructured":"Tamakoshi K, Yatsuya H, Kondo T, Hirano T, Hori Y, Yoshida T, Toyoshima H: The accuracy of long-term recall of past body weight in Japanese adult men. Int J Obes Relat Metab Disord. 2003, 27: 247-52. 10.1038\/sj.ijo.802195.","journal-title":"Int J Obes Relat Metab Disord"},{"key":"1023_CR29","unstructured":"UICC. [http:\/\/www.uicc.org\/]"},{"key":"1023_CR30","unstructured":"World Health Organization. [http:\/\/www.who.int\/en\/]"},{"key":"1023_CR31","first-page":"1862","volume":"31","author":"SA Rosenberg","year":"1971","unstructured":"Rosenberg SA, Boiron M, DeVita VT, Johnson RE, Lee BJ, Ultmann JE, Viamonte M: Report of the Committee on Hodgkin's Disease Staging Procedures. Cancer Res. 1971, 31: 1862-1863.","journal-title":"Cancer Res"},{"issue":"21","key":"1023_CR32","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.1200\/JCO.2003.02.134","volume":"21","author":"Y Vasconcelos","year":"2003","unstructured":"Vasconcelos Y, Davi F, Levy V, Oppezzo P, Magnac C, Michel A, Yamamoto M, Pritsch O, Merle-B\u00e9ral H, Maloum K, Ajchenbaum-Cymbalista F, Dighiero G: Binet's staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia. J Clin Oncol. 2003, 21 (21): 3928-32. 10.1200\/JCO.2003.02.134.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"1023_CR33","doi-asserted-by":"publisher","first-page":"i45","DOI":"10.1093\/annonc\/mdi818","volume":"16","author":"JL Harrouseau","year":"2005","unstructured":"Harrouseau JL, Greil R, Kloke O, ESMO Guidelines Task Force: ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of multiple myeloma. Ann Oncol. 2005, 16 (Suppl 1): i45-7. 10.1093\/annonc\/mdi818.","journal-title":"Ann Oncol"},{"key":"1023_CR34","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1007\/s001250050777","volume":"40","author":"T Gotoda","year":"1997","unstructured":"Gotoda T, Scott J, Aitman TJ: Molecular screening of the human melanocortin-4 receptor gene: identification of a missense variant showing no association with obesity, plasma glucose, or insulin. Diabetologia. 1997, 40: 976-9. 10.1007\/s001250050777.","journal-title":"Diabetologia"},{"key":"1023_CR35","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1210\/jcem.86.1.7104","volume":"86","author":"DR Brown","year":"2001","unstructured":"Brown DR, Berkowitz DE, Breslow MJ: Weight loss is not associated with hyperleptinemia in humans with pancreatic cancer. J Clin Endocrinol Metab. 2001, 86: 162-6. 10.1210\/jc.86.1.162.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9471","key":"1023_CR36","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/S0140-6736(05)66516-6","volume":"365","author":"KF Schulz","year":"2005","unstructured":"Schulz KF, Grimes DA: Multiplicity in randomised trials II: subgroup and interim analyses. Lancet. 2005, 365 (9471): 1657-61. 10.1016\/S0140-6736(05)66516-6.","journal-title":"Lancet"},{"key":"1023_CR37","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1097\/01.mco.0000165004.93707.88","volume":"8","author":"C Deans","year":"2005","unstructured":"Deans C, Wigmore SJ: Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care. 2005, 8: 265-9.","journal-title":"Curr Opin Clin Nutr Metab Care"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-8-85.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-8-85\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-8-85","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-8-85.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T02:04:43Z","timestamp":1630461883000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-8-85"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3,31]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["1023"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-8-85","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3,31]]},"assertion":[{"value":"25 July 2007","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2008","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2008","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"85"}}